Fmr LLC Bicycle Therapeutics PLC Transaction History

Fmr LLC

$1.68 Trillion
Q2 2025

A detailed history of Fmr LLC transactions in Bicycle Therapeutics PLC stock. As of the latest transaction made, Fmr LLC holds 316 shares of BCYC stock, worth $2,651. This represents 0.0% of its overall portfolio holdings.

Number of Shares

316

Previous 316 -0.0%

Holding current value

$2,651

Previous $2,000 -0.0%

% of portfolio

0.0%

Previous 0.0%

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2024 Feb 13, 2025	SELL	$13.81 - $27.5 $2.07 Million - $4.13 Million	-150,200 Reduced 99.79%	316 $4,000
Q3 2024 Nov 13, 2024	BUY	$19.58 - $27.24 $2.95 Million - $4.1 Million	150,516 New	150,516 $3.41 Million
Q3 2023 Nov 13, 2023	SELL	$19.9 - $26.25 $413,919 - $546,000	-20,800 Reduced 7.24%	266,347 $5.35 Million
Q1 2023 May 11, 2023	SELL	$20.02 - $31.37 $1.81 Million - $2.84 Million	-90,500 Reduced 23.96%	287,147 $6.11 Million
Q4 2022 Feb 13, 2023	SELL	$20.37 - $32.9 $5.85 Million - $9.45 Million	-287,159 Reduced 43.19%	377,647 $11.2 Million
Q3 2022 Nov 10, 2022	SELL	$17.49 - $28.44 $756,862 - $1.23 Million	-43,274 Reduced 6.11%	664,806 $15.5 Million
Q2 2022 Aug 12, 2022	SELL	$12.95 - $46.99 $1.24 Million - $4.5 Million	-95,668 Reduced 11.9%	708,080 $11.9 Million
Q1 2022 May 13, 2022	SELL	$40.12 - $59.5 $26.4 Million - $39.1 Million	-657,134 Reduced 44.98%	803,748 $35.3 Million
Q4 2021 Feb 14, 2022	BUY	$41.7 - $61.14 $41.7 Million - $61.1 Million	999,253 Added 216.46%	1,460,882 $88.9 Million
Q3 2021 Nov 15, 2021	BUY	$27.95 - $44.24 $6.99 Million - $11.1 Million	250,185 Added 118.32%	461,629 $19.2 Million
Q2 2021 Aug 13, 2021	BUY	$27.0 - $32.28 $5.71 Million - $6.83 Million	211,444 New	211,444 $6.42 Million

Others Institutions Holding BCYC

# of Institutions

118

Shares Held

42.1M

Call Options Held

111K

Put Options Held

16.6K

View Full List

About BICYCLE THERAPEUTICS plc

Ticker BCYC
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 29,676,100
Market Cap $249M
Description
Bicycle Therapeutics plc, a clinical-stage biopharmaceutical company, develops a class of medicines for diseases that are underserved by existing therapeutics. Its lead product candidate is BT1718, a bicycle toxin conjugate (BTC), which is in Phase I/IIa clinical trials targeting tumors that express Membrane Type 1 matrix metalloprotease. The co...

More about BCYC

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Fmr LLC, based on Form 13F filings with the SEC.

News

Stay updated on Fmr LLC with notifications on news.

Account